Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 5, 2010, Pages 511-517

  Kawamura, Mitsuharu ^a   Ito, Hiroyuki ^a   Onuki, Tatsuya ^a   Miyoshi, Fumito ^a   Watanabe, Norikazu ^a   Asano, Taku ^a   Tanno, Kaoru ^a   Kobayashi, Youichi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blockers; Antiarrhythmic therapy; Atrial fibrillation; Bepridil; Type III procollagen N peptide

Indexed keywords

BEPRIDIL; CANDESARTAN; CARVEDILOL; DIGITALIS; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; WARFARIN;

AGED; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; LOW DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; SINUS RHYTHM; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BEPRIDIL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 77952983248     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d70690     Document Type: Article

References (34)

1. Daoud EG, Marcovitz P, Knight BP, et al. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation. 1999;99:3024-3027.
2. Fujiki A, Tsuneda T, Sugao M, et al. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol. 2003;92:472-475.
3. Yoshida T, Niwano S, Inuo K, et al. Evaluation of the effect of bepridil on paroxysmal atrial fibrillation. Circ J. 2003;67:11-15.
4. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias; inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.
5. Bruins P, Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548.
6. Raffaella L, Sandro B, Maria Angela L, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455-1460.
7. Host NB, Jensen LT, Bendixen PM, et al. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1995;76:869-873.
8. Puhakka M, Magga J, Hietakorpi S, et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Card Fail. 2003;9:325-332.
9. Schwartzkopff B, Fassbach M, Pelzer B, et al. Elevated serum markers of collagen degration in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002;4:439-444.
10. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on Losartan or Atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110:552-557.
11. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004;10:403-411.
12. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544-1548.
13. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J. 2005;150:1064.e7-1064.e12.
14. Liu T, Li L, Korantzopoulos P, et al. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. Am J Cardiol. 2008;101:1749-1752.
15. Polyakova V, Miyagawa S, Szalay Z, et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med. 2008;12:189-208.
16. Timonen P, Magga J, Risteli J, et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol. 2008;124:293-300.
17. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation. 2003;107:2926-2931. (Pubitemid 36736634)
18. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.
19. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719.
20. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-557.
21. Madrid AH, Bueno MG, Rebollo JM, et al. Use of @irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-336.
22. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A Meta-Analysis. J Am Coll Cardiol. 2005;45:1832-1839.
23. Disertori M, Latini R, Staszewsky L, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-1617.
24. DiBianco R, Alpert J, Katz RJ, et al. Bepridil for chronic stable angina pectoris: results of a prospective multi-center, placebo controlled, doseranging study in 77 patients. Am J Cardiol. 1984;53:35-41.
25. Anno T, Furuta T, Itoh M, et al. Effects of bepridil on the electrophysiological propertiesofguinea-pigventricularmuscles. Br J Phamacol. 1984;81:41-47.
26. Wang JC, Kiyosue T, Kiriyama K, et al. Bepridil differently inhibits two delayed rectifier K+ currents, Ikr and Iks, in guinea-pig ventricular myocytes. Br J Phamacol. 1999;128:1733-1738.
27. Harder DR, Sperelakis N. Bepridil blockade of Ca2+-dependent action potentials in vascular muscle of dog coronary artery. J Cardiovasc Pharmacol. 1981;3:906-914.
28. Nakazato Y, Yasuda M, Sasaki A, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J. 2005;69:44-48.
29. Yasuda M, Nakazato Y, Sasaki A, et al. Clinical evaluation of adverse effects during bepridil administration atrial fibrillation and flutter. Circ J. 2006;70:662-666.
30. Merritt JC, Niebauer M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol. 2003;92:735-736.
31. Katritsis DG, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol. 2003;92:1116-1119.
32. Ohtsuka T, Hamada M, Saeki H, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:996-999. (Pubitemid 34310306)
33. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147:324-330.
34. Xie HG, Kim RB, Wood AJ, et al. Molecular Basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850.